FinArc Investments Inc. Takes $1.15 Million Position in AbbVie Inc. $ABBV

Posted by on Jul 31st, 2026

FinArc Investments Inc. acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,269 shares of the company’s stock, valued at approximately $1,146,000. AbbVie makes up about 1.1% of FinArc Investments Inc.’s holdings, making the stock its 28th largest holding.

Other hedge funds also recently bought and sold shares of the company. Bank of Jackson Hole Trust grew its holdings in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares during the last quarter. Eclectic Associates Inc. ADV raised its position in AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after purchasing an additional 45 shares during the period. Imprint Wealth LLC lifted its stake in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Dogwood Wealth Management LLC lifted its stake in AbbVie by 10.8% in the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after purchasing an additional 46 shares during the last quarter. Finally, Quantum Private Wealth LLC boosted its position in AbbVie by 2.0% during the fourth quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock valued at $543,000 after buying an additional 46 shares during the period. Institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

  • Positive Sentiment: The European Commission approved RINVOQ® for severe alopecia areata in adults and adolescents aged 12 and older. The Phase 3 program demonstrated statistically significant scalp, eyebrow, and eyelash hair regrowth, including complete scalp regrowth for some patients. The approval expands RINVOQ’s commercial opportunity in Europe. RINVOQ alopecia areata approval
  • Positive Sentiment: RINVOQ also received EU approval for non-segmental vitiligo, making it the first and only systemic treatment approved for that condition in the region. The decision was supported by positive Phase 3 repigmentation data and could further diversify RINVOQ growth. RINVOQ vitiligo approval
  • Positive Sentiment: AbbVie began a first-in-human Phase 1 trial of ABBV-859, providing an early-stage pipeline catalyst. The program is not expected to affect near-term earnings, but investors may view it as evidence of continued investment in long-term growth. ABBV-859 Phase 1 trial
  • Positive Sentiment: Unusually heavy call-option buying and a modest increase in an analyst’s 2027 earnings forecast indicate that some traders and analysts remain bullish on AbbVie’s longer-term earnings outlook.
  • Neutral Sentiment: Allergan Aesthetics will hold its annual JUVÉDERM® Day on August 19, supporting consumer engagement and the aesthetics franchise, although the promotional event is unlikely to materially change near-term financial results. JUVÉDERM Day announcement
  • Neutral Sentiment: Investors are also focused on AbbVie’s second-quarter earnings report due July 31. A slight reduction in one 2026 earnings estimate was offset by a higher 2027 forecast, leaving expectations mixed ahead of the report.
  • Negative Sentiment: AbbVie’s proposed acquisition of Apogee Therapeutics faces an investigation into the deal’s price and transaction process. While the review does not establish wrongdoing, it introduces regulatory and execution uncertainty around the transaction. Apogee transaction investigation
  • Negative Sentiment: After a strong multi-year rally, valuation concerns and potential profit-taking may be pressuring ABBV, particularly with the shares trading near their 52-week high and at a rich earnings multiple.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. increased their target price on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Wells Fargo & Company raised their price target on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, July 10th. Canaccord Genuity Group lifted their price target on AbbVie from $273.00 to $282.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Finally, Bank of America boosted their price objective on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Check Out Our Latest Stock Analysis on ABBV

AbbVie Stock Performance

ABBV opened at $257.57 on Friday. AbbVie Inc. has a 52-week low of $187.62 and a 52-week high of $267.47. The stock has a market capitalization of $455.07 billion, a PE ratio of 126.88, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. The stock’s 50 day moving average price is $238.39 and its 200-day moving average price is $223.86.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 earnings per share. Research analysts forecast that AbbVie Inc. will post 14.14 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio is 340.89%.

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Read More

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.